



Company News

Proposed Issue of US\$180 Million Guaranteed Convertible Bonds to Support Industry Chain Layout

On 23 January 2020, Viva Biotech announced the proposed issue of US\$180 million 2.50% guaranteed convertible bonds due 2025 by Viva Incubator Investment Management Limited. Bonds will be convertible into fully paid ordinary share of Viva Biotech at the initial conversion price of HK\$5.7456 per share, which represents a premium of 26.0% over the last closing price on 22 January 2020. The proceeds will be used for business development and expansion.

Acquisition of Shanghai Pudong Zhangjiang Hi-Tech Park Self-use Property

On 21 January 2020, Viva Biotech announced the acquisition of 100% equity interest of the Shanghai Shenyu Wires Co., Ltd at a consideration of RMB 120 million. The acquired company holds the property located at Shanghai with the total site area of 7,576 sq.m., containing four blocks of buildings in Zhangjiang Hi-Tech Park, Pudong, Shanghai. The property is intended to be held by Viva Biotech for self-use. The acquisition will reduce rental expenses and provide stable office and operation space for Viva Biotech and allow the Company to meet its business development plans.

Viva Biotech Attended the J.P. Morgan Healthcare Conference to Share the Views on "Innovation and Cooperation"

From 13 to 16 January 2020, Viva Biotech was invited to attend the 38th J.P. Morgan Healthcare Conference in San Francisco, gathering with global bio-pharmaceutical investors to discuss the future development trend of the industry and global capital markets movements. Dr. Cheney Mao, Chairman and CEO of Viva Biotech, was invited to deliver a keynote speech at the Golden Gate as a main forum guest.



During the JPM Healthcare Conference, the RESI San Francisco 2020, hosted by the Life Science Nation and proudly sponsored by Viva Biotech, gave some speeches with forward-looking insights for the participants. As the largest pre-clinical investment conference for biotech start-ups in North America, RESI 2020 attracted over 1,200 participants, in which more than 500 were founders of bio-pharmaceutical start-ups. Dr. David Xu, Chief Business Officer of Viva Biotech, spoke at the "China's Cross-Border Cooperation" session as a guest.

Dr. Delin Ren: More Innovative Drugs will Step Into International Markets from China

On 20 November 2019, Dr. Delin Ren, Executive Director and General Manager of Viva Biotech was invited to attend the "First Financial Science and Technology Innovation Conference" and the first "Hua Chuang Award" and the sixth "Hua Xin Award" award ceremony. Dr. Ren gave a speech on the event and expressed his belief that more innovative drugs will be born in China and step into the international markets in the future.



Viva Biotech Partnership Summit Successfully Launched in Shanghai

2019 Viva Biotech Partnership Summit was successfully launched on 8 November 2019 in Pudong, Shanghai, themed "Innovation Partnership Growth" to discuss how to help global biotech startups to realize the transition from 0 to 1 and commercialization through Innovation, Partnership and Growth. During the 4-days Summit, 116 1-on-1 meetings were hosted. Dozens of investors showed great interests towards the innovative and biopharmaceutical companies incubated or invested by Viva.



Specialization and Differentiation - Sharing of Innovative Model of Viva Biotech at China Renaissance Healthcare Summit

On 31 October and 1 November, the 7th China Renaissance Healthcare and Life Sciences Leadership Summit was held in Shanghai. In the forum themed "Strategic Transformation of Innovative CRO Enterprises in the New Pattern", Dr. David Xu, Chief Business Officer and Director of Viva Biotech Innovation Center, participated in the guest discussion and expressed Viva Biotech's perspective on the current status and future development trends of the CRO industry, thinking that every company needs to take the route of specialization and differentiation.



Return on Incubation Investment

Viva Biotech Sold 4% Share of Proviva Therapeutics

On 31 December 2019, Viva Biotech sold 4% of the fully diluted equity shares of its incubated company Proviva Therapeutics with an aggregate consideration of 4 million US dollars. The Company's equity interest in Proviva Therapeutics on a fully diluted basis after taking into account its employee incentive share reserves reduced from 35.0% to 31.0% upon the completion of the disposal. The net proceeds arising from the disposal were used as general working capital of the Group.

Viva Biotech Sold Approximately 2.4% Share of Weimou Biotech

On 29 October 2019, Viva Biotech sold approximately 2.4% of the entire issued share capital of Weimou Biotech at the consideration of US Dollar equivalent of RMB 10 million. After the completion of the disposal, Viva Biotech's equity interest in Weimou Biotech reduced from approximately 8.56% to approximately 6.16%. The net proceeds arising from the disposal were used as general working capital of the Group.



Market Recognition

Viva Biotech Awarded Golden Hong Kong Stocks 'Most Popular Newly Listed Company'

On 9 January 2020, Viva Biotech was granted the title of the 'Most Popular Newly Listed Company' award on the fourth annual Golden Hong Kong Stocks Awards organised by Zhitongcaijing.com, proving the industry and investors' full recognition of Viva Biotech's strong R&D service strength and innovative business model.



Viva Biotech Awarded 'Top 10 Public Companies', Fostering Value Creation and Discoveries of Innovative Drugs from 0 to 1

On 20-22 December 2019, The 'Future Healthcare VB 100 Summit' organized by VCBeat and VCBeat Research was held in Beijing. Viva Biotech was invited to the Summit and awarded the 'Top 10 Public Companies 2019' with honor. Dr. David Xu, the Chief Business Officer of Viva Biotech, was invited to deliver a keynote speech themed 'Early-stage Investment of Innovative Drugs: Valuation and Orientation'.



Inclusion in the Hang Seng Hong Kong-Listed Biotech Index

On 18 December 2019, as the world's leading operator of structure-based new drug discovery technology platforms, Viva Biotech Holdings (1873.HK) was included as a constituent stock of the Hang Seng Hong Kong-Listed Biotech Index.



Viva Biotech Awarded 'Outstanding Listed Company'

On 18 December 2019, 'Infinity π, Create the Future' 2019 Zhangjiang S&T Investment Annual Communication Forum was held in Shanghai. Viva Biotech was invited to attend the forum and granted the award of 'Outstanding Listed Company' by Zhangjiang S&T Investment.



Viva Biotech LinkedIn

Research & Development Process



ABM Therapeutics' BRAF Inhibitor ABM-1310 Obtained Clinical Trials Approval from the US FDA

ABM Therapeutics, a biomedical innovation company invested by Viva Biotech in its A round investment, announced that its self-developed ABM-1310, a new generation of BRAF inhibitor has obtained clinical trial approval from the US Food and Drug Administration (FDA).

Investment Progress



DTx Pharma Completed its Series A Funding

On January 10, 2020, DTx Pharma, a San Diego biopharmaceutical startup company invested by Viva Biotech, announced that its A round financing amounted to USD10.6 million was completed. DTx Pharma plans to use the proceeds to accelerate the development and deployment of its proprietary platform to advance RNA drug R&D.

About Viva Biotech

Listing Date

2019.05.09

Price (2020.2.17)

HKD 4.31

52 WK

HKD 3.15-5.45

Market Cap (2020.2.17)

HKD 6.73B

Viva Biotech's mission is to become a cradle for innovative biotechnology companies around the world. Viva Biotech has developed a scalable business model combining the conventional cash-for-service (CFS) model and its unique equity-for-service (EFS) model. Under the CFS model, the Group provides structure-based drug discovery services to its biotechnology and pharmaceutical customers worldwide for their pre-clinical stage innovative drug development, covering the full spectrum of the customers' needs for early stage drug discovery, including target protein expression and structure research, hit screening, lead optimization and drug candidate determination. Viva Biotech also provides drug discovery and incubation services to biotechnology start-up companies with high potential under its EFS model. As of June 30, 2019, Viva Biotech had provided drug discovery services to 388 biotechnology and pharmaceutical customers worldwide, worked on over 1,000 independent drug targets, delivered over 11,000 independent protein structures, and incubated a total of 37 early stage R&D projects.

Investor & Media Enquiries

Viva Biotech Holdings website: www.vivabiotech.com.cn

For further information, please contact:

Email : VivaBiotech.hk@pordahavas.com

Tel : 852-3150 6788

